WIC
MRNA icon

Woodmont Investment Counsel’s Moderna MRNA Stock Holding History

Woodmont Investment Counsel’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21,188
Closed -$1.42M – 265
2024
Q3 		$1.42M Buy
21,188
+8,218
+63% +$755K 0.11% 115
2024
Q2 		$1.54M Sell
12,970
-2,166
-14% -$274K 0.13% 107
2024
Q1 		$1.61M Buy
15,136
+70
+0.5% +$7.06K 0.14% 104
2023
Q4 		$1.5M Buy
15,066
+5,766
+62% +$485K 0.14% 105
2023
Q3 		$961K Buy
9,300
+960
+12% +$107K 0.1% 133
2023
Q2 		$1.01M Sell
8,340
-532
-6% -$71K 0.11% 131
2023
Q1 		$1.36M Buy
8,872
+315
+4% +$52K 0.14% 114
2022
Q4 		$1.54M Sell
8,557
-280
-3% -$45.8K 0.17% 106
2022
Q3 		$1.04M Sell
8,837
-35
-0.4% -$5.31K 0.13% 124
2022
Q2 		$1.27M Buy
+8,872
New +$1.27M 0.16% 112

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Woodmont Investment Counsel's MRNA Position: Q4 2024 in Review

Woodmont Investment Counsel sold out of Moderna (MRNA) in Q4 2024, closing a stake of 21,188 shares — an estimated $1.42M sold.

Woodmont Investment Counsel first reported a position in MRNA in Q2 2022 and held it in 10 quarters. The position peaked at $1.61M in Q1 2024. 746 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Woodmont Investment Counsel reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Woodmont Investment Counsel sold 21,188 Moderna shares in Q4 2024, an estimated $1.42M.
  • Woodmont Investment Counsel first reported a position in Moderna in Q2 2022 and held it in 10 quarters.
  • Woodmont Investment Counsel's Moderna position peaked at $1.61M in Q1 2024.
  • 746 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Woodmont Investment Counsel's 13F filing for Q4 2024, filed 11 Feb 2025.